Analysts anticipate Bionano Genomics to report an earnings per share (EPS) of $-0.21.
The market awaits Bionano Genomics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
Past Earnings Performance
In the previous earnings release, the company beat EPS by $0.18, leading to a 6.72% drop in the share price the following trading session.
Here's a look at Bionano Genomics's past performance and the resulting price change:
Quarter
Q2 2024
Q1 2024
Q4 2023
Q3 2023
EPS Estimate
-0.42
-0.64
-0.87
-0.94
EPS Actual
-0.24
-0.60
-0.96
-1.01
Price Change %
-7.000000000000001%
7.000000000000001%
2.0%
-2.0%
Stock Performance
Shares of Bionano Genomics were trading at $0.2781 as of November 11. Over the last 52-week period, shares are down 79.93%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.
Analysts' Take on Bionano Genomics
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Bionano Genomics.
Analysts have provided Bionano Genomics with 1 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $1.0, suggesting a potential 259.58% upside.
Understanding Analyst Ratings Among Peers
In ...
